Debiopharm International Sa

This study is testing a new drug called Debio 0123 for adults with glioblastoma, a fast-growing brain cancer. The goal is to see if adding this drug to standard chemotherapy (temozolomide) and radiation is safe and can help control the cancer better. The research will first find …

This study is testing a new long-acting injection called Debio 4228 for men with advanced prostate cancer. The goal is to find the best dose that safely lowers testosterone levels to help control cancer growth. Researchers will measure how the drug moves through the body and how …

This early-stage trial is testing a new drug called Debio 1562M for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The study aims to find a safe dose and see if the drug can reduce or eliminate leukemia cells. Participants will…

This early-stage study is testing a new oral drug called lunresertib, both alone and in combination with two other experimental drugs, for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe dose levels, understan…

This study is testing a new, long-acting injection called Debio 4126 for people with acromegaly, a rare hormonal disorder. The goal is to see if one shot every 12 weeks can keep a key hormone (IGF-1) at a safe level, compared to a placebo. It will also check the safety and side e…

This is a very early, first-in-human study to check the safety and how the body processes a new oral drug called Debio 1453P. It will involve 88 healthy adults who will receive either the drug or a placebo. The main goal is to see how well different doses are tolerated and to mea…